<DOC>
	<DOCNO>NCT02348606</DOCNO>
	<brief_summary>This trial 12 week , randomize , double-blind , placebo control , multicenter , 5-arm parallel group study safety efficacy JZP-110 treatment excessive sleepiness adult subject OSA .</brief_summary>
	<brief_title>`` Twelve-week Study Safety Efficacy JZP-110 Treatment Excessive Sleepiness OSA ''</brief_title>
	<detailed_description />
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>Major 1 . Male female 18 75 year age , inclusive 2 . Diagnosis OSA accord ICSD3 criterion 3 . Body mass index 18 &lt; 45 kg/m2 4 . Consent use medically acceptable method contraception 5 . Willing able provide write informed consent Major 1 . Female subject pregnant , nursing , lactate 2 . Any clinically relevant medical , behavioral , psychiatric disorder OSA associate excessive sleepiness 3 . History presence bipolar disorder , bipolar related disorder , schizophrenia , schizophrenia spectrum disorder , psychotic disorder accord DSM5 criterion 4 . History presence acutely unstable medical condition , behavioral psychiatric disorder ( include active suicidal ideation ) , surgical history could affect safety subject interfere study efficacy , safety , PK assessment , ability subject complete trial per judgment Investigator . 5 . History bariatric surgery within past year history gastric bypass procedure 6 . Presence history significant cardiovascular disease 7 . Use overthecounter ( OTC ) prescription medication could affect evaluation excessive sleepiness 8 . Received investigational drug past 30 day five halflives 9 . Previous exposure participation clinical trial JZP110 ( ADXN05 , R228060 , YKP10A ) 10 . History phenylketonuria ( PKU ) history hypersensitivity phenylalaninederived product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>